Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity RequirementGlobeNewsWire • 09/16/26
Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity IssuanceGlobeNewsWire • 08/03/26
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity RequirementGlobeNewsWire • 06/10/26
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-QGlobeNewsWire • 06/01/26
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)GlobeNewsWire • 04/22/26
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative ActionsGlobeNewsWire • 04/02/26
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing TransplantGlobeNewsWire • 02/05/26
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem MeetingsGlobeNewsWire • 01/21/26
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual MeetingGlobeNewsWire • 12/08/25
New Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual MeetingGlobeNewsWire • 11/03/25
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/22/25
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing RequirementsBusiness Wire • 08/04/25
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantBusiness Wire • 08/01/25
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-QBusiness Wire • 05/28/25
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous TransplantBusiness Wire • 05/05/25
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple MyelomaBusiness Wire • 04/14/25